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Abstract
Background: The goal of this prospective study was to determine (a) concentrations of the carbohydrate
biomarkers Thomsen Friedenreich (TF) antigen and its precursor, Tn antigen, in nipple discharge (ND) collected
from women requiring biopsy because of a suspicious breast lesion; and (b) if concentration levels predicted
pathologic diagnosis.
Methods: Adult women requiring biopsy to exclude breast cancer were enrolled and ND obtained. The samples
from 124 women were analyzed using an anti-TF and anti-Tn monoclonal antibodies in direct immunoassay.
Results: The highest median concentration in ND for TF and Tn was in women with ductal carcinoma in situ
(DCIS). TF was higher in women with 1) cancer (DCIS or invasive) vs. either no cancer (atypia or benign pathology,
p = .048), or benign pathology (p = .018); and 2) abnormal (atypia or cancer) versus benign pathology (p = .016);
and was more predictive of atypia or cancer in post- compared to premenopausal women. Tn was not predictive
of disease. High TF concentration and age were independent predictors of disease, correctly classifying either
cancer or abnormal vs. benign pathology 83% of the time in postmenopausal women.
Conclusions: TF concentrations in ND were higher in women with precancer and cancer compared to women
with benign disease, and TF was an independent predictor of breast atypia and cancer. TF may prove useful in
early breast cancer detection.
Background
The Thomsen-Friedenreich (TF; Galactose-b-(1®3)-N-
acetyl-D-galactosamine) antigen and its biosynthetic pre-
cursor, Tn (N-acetyl-D-galactosamine), are displayed on
cell-surface proteins and lipids in 70% to 90% of adeno-
carcinomas including those of the breast, prostate, and
ovary [1]. Antibodies to TF and Tn have been used
clinically as indicators of cancer and have been detected
in primary breast cancer, lymph node, and metastatic
tissue samples [2,3]. Obtaining tissue samples requires
invasive biopsy procedures, which result in expense and
considerable discomfort to the patient. An attractive
alternative would be to screen a body fluid sample
obtained non-invasively to determine if the organ con-
tains cancer, thereby minimizing invasive diagnostic pro-
cedures. Nipple discharge (ND) includes both nipple
aspirate fluid (NAF), which is collected using a modified
breast pump, and pathologic (P)ND, which comes forth
spontaneously from one but not the other breast nipple
and generally harbors a benign or malignant tumor [4].
Both types of ND can be obtained non-invasively and
contain concentrated secreted proteins and lipids from
the breast ductal epithelium, the cells that give rise to
cancer.
We hypothesized that TF and Tn antigen, displaced
on proteins and lipids that arise from cancer cells and
cancer cell turnover, would be present in ND. To test
this hypothesis, an initial blinded screening of 50 banked
NAF samples from women with breast cancer and from
asymptomatic women without cancer were screened for
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preliminary study demonstrated significant differences
in the expression of TF and Tn between NAF from a
breast with cancer compared to asymptomatic women
[5]. Based on the encouraging findings, we instituted a
multicenter prospective clinical trial in women with a
breast lesion requiring diagnostic biopsy to exclude
cancer.
Methods
Patients and Sample Collection
After receiving Institutional Review Board approval from
the three institutions listed below, informed consent was
obtained from all subjects prior to enrollment. 166 sub-
jects were prospectively enrolled and samples collected
in Grand Forks, ND at the University of North Dakota,
in Columbia, MO at the Ellis Fischel Cancer Center and
in London, UK at the Royal Marsden Cancer Center.
Participants were enrolled from September 2005 to Feb-
ruary 2008. The time between sample collection and
analysis ranged from 0.7 to 25.9 months, with a median
of 7.3 months. A subject was classified as postmenopau-
sal if at least one year had passed without a menstrual
period or she had undergone bilateral oophorectomy
prior to enrollment. Women who had undergone hyster-
ectomy without bilateral oophorectomy were considered
postmenopausal if they were over 50 years old. If follicle
stimulating hormone (FSH) levels were available, a level
of 34 mIU/mL or greater was used to classify women as
postmenopausal. There were four women in this cate-
gory. All ND samples were collected prior to surgical
biopsy. All comparisons of TF and Tn concentrations
with disease were based on the histopathologic findings
in the clinical report.
ND samples
ND (1-10 μL) samples were obtained from the breast
with a lesion prior to surgery. Lesions included women
with 1) PND; 2) a suspicious lesion identified on ima-
ging, be it mammogram, ultrasound or breast magnetic
resonance imaging; and/or 3) a palpable lesion that was
not a simple cyst. Samples were collected as described
previously [6]. Briefly, after informed consent was
o b t a i n e d ,N Df l u i dw a sa s p irated using a breast pump
(NAF) or collected after the participant massaged her
breast (PND). Samples were collected into capillary
tubes and stored at -80°C until use.
Assessment of TF and Tn
ND samples from women with and without breast can-
cer were analyzed in blinded fashion. All assays were
run in triplicate. It was initially thought that an indirect
immunoassay would be more sensitive than a direct
assay to small changes in TF and Tn concentration, so
the 42 initially collected ND samples were analyzed
using an indirect sandwich immunoassay. The indirect
method entailed capturing TF and Tn antigen molecules
in NAF on an antibody coated surface. The surface was
interrogated with a biotinylated TF or Tn ligand. Ligand
binding was determined by a streptavidin-alkaline phos-
phate color reaction. TF and Tn concentrations were
inversely proportional to the reporter signal. This assay
proved unreliable, so a direct assay was developed and
proved more reliable. Herein we present results for the
124 ND samples that were analyzed using a direct
immunoassay.
Reagents
All reagents were purchased from Sigma (Sigma Chemi-
cal, St. Louis, MO) unless specifically noted. The anti-
TF antibody A78-G/A7 was purchased from Glycotope
(Berlin, Germany) and the BRIC-111 anti-Tn antibody
was purchased from Serotec (Oxford, UK). Both antibo-
dies were raised against desialylated red blood cells of
the appropriate blood group. The TF Ab is specific for
both anomeric forms of the disaccharide, including
related structures on the g l y c o l i p i d sa n ds h o w sn o
cross-reactivity with sialylated glycophorin [7]. The Tn
antibody is specific for the alpha O-linked N-acetyl-D-
galactosamine. The alpha-O linkage appears to be
important. Biotinylation of antibodies and lectins was
performed according to published procedures [7].
TF and Tn Direct Immunoassay
Each NAF sample was assayed in triplicate on the same
ELISA plate for TF or Tn and the mean values were
reported to the statistician. Anti-TF and anti-Tn monoclo-
nal antibodies (200 ng/well) in a 0.1 M sodium carbonate
pH 9.6 buffer were applied to Nunc-immunomax 96-well
plates for 4 h at 37°C. The plates were washed with Tris-
buffered saline pH 8.0 containing 0.5% Tween-20 (TTBS)
and blocked with 2% bovine serum albumin (BSA) in
TTBS for 2 h. One-hundred microliters of diluted ND
samples (1:50-1:500) in Tris-buffered saline pH 8.0 (TBS)
were added to the wells. Control wells contained various
dilutions of asialofetuin (ASF) or asialo-ovine submaxillary
mucin (OSM) in TBS (0 ng - 2 ng/well). ASF contains TF
antigen while AOSM contains exposed Tn antigen. The
ND, ASF and OSM samples were incubated at 25°C for 2
h followed by a TTBS wash. Biotinylated secondary detec-
tion proteins, anti-TF antibody (0.625 μg/ml) or Tn bind-
ing Vicia villosa lectin (1 μg/mL) in 100 μLT B S ,w e r e
added to the wells and incubated for 1 hr. The unbound
secondary detection proteins were removed by two washes
with TTBS, while the bound biotinylated secondary detec-
tion proteins were bound with a streptavidin-horse radish
peroxidase conjugate (SA-HRP) (100 μL/well of a 1 μg/mL
stock) for 1 hour at 25°C. Unbound SA-HRP was removed
by two TTBS washes and the wells were developed with
100 μL/well of the chromogenic substrate 2, 2’-Azino-bis
(3-ethylbenzothiazoline-6-sulfonic) (Sigma) detected at
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Page 2 of 7405 nm. A standard curve was performed on each plate
for either TF or Tn. A range of known concentrations of
TF or Tn displaying proteins, asialofetuin (TF) or ovine
salivary mucin (Tn), were assayed. This allowed us to
compare results from plate to plate and account for varia-
tion between plates. The data were reported as absorbance
(Abs) at 405 nm per microliter of ND. The overall average
between batch % coefficients of variation (%CVs) for TF
and Tn were 5.5 and 8.9, respectively. The within batch
average %CVs were 4.3 and 5.9, respectively. The intraclass
correlation coefficient (ICC) for TF is .73 (95% CI .63 -
.80) and for Tn it is .68 (95% CI .58 - .77).
Statistical analysis
Biomarker levels for TF and Tn in the ND samples were
heavily skewed and not normally distributed. We there-
fore described and analyzed TF and Tn biomarker levels
using medians and log-transformed (Log10) means to
achieve normal distributions. Univariate analyses using
the Mann-Whitney-Wilcoxon signed ranks test were
performed to determine median biomarker levels while
t-tests were calculated to determine log10 means of the
biomarkers. Logistic regression analyses are based on
log10 transformed data. Three logistic regression models
were used to examine the effects of TF, Tn, and meno-
pausal status (pre-vs. post-menopausal) in predicting (a)
cancer vs. no cancer diagnosis; (b) cancer vs. benign
diagnosis; and (c) abnormal vs. benign diagnosis.
Because menopausal status was a near significant pre-
dictor in all three overall logistic models, follow-up
logistic models were conducted separately for premeno-
pausal women and for postmenopausal women, control-
ling for age. ROC curves were calculated based on the
logistic regression results for the postmenopausal
women’s data, and AUC values are presented.
Results
Recruitment
Of 137 women, we successfully collected NAF in 111 of
124 (90%) and PND in 13/13 (100%).
Among the 124 women evaluated, 72 (58%) were post-
menopausal. Ages ranged from 19-86 years, with a med-
ian age in pre- and postmenopausal women of 45 and
61, respectively. Thirty-seven postmenopausal women
took hormone replacement therapy (HRT) at one point
in their lives, with nine taking HRT at the time of NAF
collection. HRT use did not significantly influence the
ability of TF or Tn to predict either breast abnormal
pathology or cancer. Eighty-three (67%) of the partici-
pants were found to have breast cancer (11 DCIS and
72 invasive), and 41 (33%) benign disease (7 AH, 28 H,
and 6 normal pathology).
Fluid Volume and Biomarker expression not different
among women with vs. those without PND
ND volume ranged from 0.5-546 microliters, with a
mean of 53 and median of 25 microliters. ND volume
did not vary by pathologic diagnosis nor by fluid type
(NAF vs. PND). We first determined if TF and Tn
expression in women requiring diagnostic biopsy due to
PND differed from expression in women requiring
biopsy who did not have PND. Results of logistic regres-
sion analyses conducted with women with PND (n =
1 3 )a n dN A F( n=1 1 1 )w e r ee q u i v a l e n tt or e s u l t s
obtained from analyses conducted with only women
providing NAF. Therefore, all reported analyses include
both PND and NAF samples (N = 124).
Biomarker expression increases with the development of
precancerous changes in the breast
Median concentrations of TF and Tn were 7 and 3 fold
higher, respectively (Figure 1), in women with atypical
compared to those with usual hyperplasia (H). The dif-
ference in TF expression was significant (p = .043),
despite limited sample size in the atypical hyperplasia
group. The highest median concentration of TF and Tn
were in women with ductal carcinoma in situ (DCIS).
TF expression trended higher in women with DCIS
compared to those with usual hyperplasia (p = .09) and
normals (p = .07).
TF Concentration is associated with breast atypia and
cancer
Univariate analysis indicated that TF concentration was
higher in women with abnormal (atypia or cancer) than
benign pathology (p = .016, Table 1). TF was also higher
in women with cancer (DCIS or invasive) than in
women with 1) no cancer: atypia or benign pathology (p
= .048), and 2) benign pathology (p = .018). Tn concen-
tration was not significantly associated with either
abnormal pathology or cancer.
TF and Tn expression based on menopausal status
We analyzed samples based on menopausal status to
determine if these markers had greater predictive ability
in one or the other population of women. Univariate
analyses indicated that TF was a greater predictor of
breast atypia and cancer among post- than among pre-
menopausal women. TF concentration was higher in
postmenopausal women with abnormal than benign
pathology (Table 1, p = .007), and in cancer (DCIS or
invasive) than in women with 1) no cancer (p = .025),
and 2) benign pathology (p = .007). Tn concentration
was not significantly associated with abnormal pathology
or cancer in either pre- or postmenopausal women.
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Logistic regression was conducted involving TF, Tn, and
age for the following predictive groups: cancer vs. no
cancer, cancer vs. benign pathology, and abnormal vs.
benign pathology (Table 2). Each of these models
demonstrates that in post- but not premenopausal
women, high TF (odds ratios (OR) ranging from 8.53-
15.56) and increasing age are independent predictors of
disease (p < .05), whereas Tn concentration was not an
independent predictor of disease status.
ROC curves
We generated ROC curves to determine how well infor-
mation on TF, Tn and age predicted if a postmenopau-
sal woman had breast atypia or cancer. Three
comparisons: cancer vs. no cancer, cancer vs. benign
pathology, and abnormal vs. benign pathology were
conducted. The AUC values for the three comparisons
were similar, ranging from .81 - .83, with the latter two
comparisons having the best predictive ability (Figures
2A-C).
Figure 1 Median values for TF (A) and Tn (B). H = usual hyperplasia; AH = atypical hyperplasia; DCIS: ductal carcinoma in situ; invasive: invasive
breast cancer. Numbers in parentheses indicate the sample sizes for each group. Y axis units are Abs/μL. TF expression was higher in women with
AH compared to H (p = .043), and trended higher in women with DCIS compared to normals (p = .07) and women with H (p = .09).
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TF was the more predictive of disease in the breast than
Tn. Based on our earlier published work [5], we first
performed an indirect immunoassay using commercially
obtained TF and Tn antibodies. The antibodies used in
our initial report were no longer available, and the indir-
ect assay using the new antibodies yielded TF and Tn
concentration results that were variable and with a large
number of outlier values. We next compared results
using indirect and direct TF and Tn immunoassays of
the same ND samples that were analyzed in our pub-
lished report. We found that the direct immunoassays
for TF and Tn were more reliable than the indirect
assays.
We previously found that the expression of some ND
cancer prediction markers varied based on whether the
subject requiring surgery did or did not have PND [8].
We therefore determined if TF and Tn concentration
differed based on whether the sample was PND or NAF.
Since we did not identify a concentration difference, all
analyses included both PND and NAF samples.
In a study involving N-nitrosomethylurea induced rat
mammary cancer, Tn was found to be a biomarker of
precancer in both breast tissue and serum [9]. While Tn
concentrations were highest among women with DCIS
and second highest among women with atypia, differ-
ences between risk groups were not significant. We can-
not exclude the possibility that with a larger sample size
we would have found an association.
One might ask why Tn was not associated with breast
cancer, as was observed in our earlier report. First, there
was a difference in the ND sample populations between
our published report and current analyses. The first
study was a blinded analysis performed on banked NAF
samples, comparing women with breast cancer to
asymptomatic women as a no cancer control. In the
current analysis, all samples were obtained from women
requiring surgical biopsy to evaluate an abnormal
Table 1 Univariate Analyses of TF and Tn Expression in Women With an Abnormal (Atypia or Cancer) vs. a Benign
Breast Biopsy
Overall Benign
1 Abnormal
1 P value
2
All Subjects (N) 124 34 90
TF Log10 Mean (SD) .65 (.54) .46 (.48) .72 (.54) .016
Median 1.87 1.19 4.20 .015
Geometric Mean (SD) 8.55 (12.73) 5.63 (12.3) 9.65 (12.78) .12
Tn Log10 Mean (SD) .59 (.50) .54 (.50) .60 (.50) .51
Median 2.87 1.29 3.12 .57
Geometric Mean (SD) 6.47 (9.52) 5.77 (8.48) 6.73 (9.92) .62
Premenopausal (N) 52 18 34
TF Log10 Mean (SD) .71 (.54) .61 (.59) .76 (.52) .34
Median 4.53 1.66 7.71 .27
Geometric Mean (SD) 9.44 (12.48) 9.6 (16.04) 9.36 (10.4) .95
Tn Log10 Mean (SD) .58 (.46) .48 (.49) .64 (.45) .24
Median 3.25 .97 3.70 .25
Geometric Mean (SD) 5.51 (7.33) 4.71 (7.32) 5.94 (7.4) .57
Postmenopausal (N) 72 16 56
TF Log10 Mean (SD) .60 (.53) .29 (.21) .69 (.56) .007
Median 1.61 1.19 2.44 .014
Geometric Mean (SD) 7.91 (12.96) 1.17 (1.03) 9.83 (14.12) .000
Tn Log10 Mean (SD) .59 (.53) .61 (.52) .58 (.54) .88
Median 1.94 1.47 2.44 .71
Geometric Mean (SD) 7.16 (10.83) 6.96 (9.73) 7.21 (11.21) .94
1: Benign = normal and hyperplasia; Abnormal = atypical hyperplasia, ductal carcinoma in situ and invasive cancer. TF and Tn median results are in Abs/μL.
2: P value for Log10 and geometric means are based on the t-test; P value for medians are based on the Mann-Whitney-Wilcoxon test.
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possible that since all women in the current study had
an abnormality that required surgical biopsy, this raised
the background of the assay making it more difficult to
distinguish cancer from benign.
TF and Tn concentrations were notably higher in
women with AH compared to those with benign disease.
There are two highly effective chemopreventive agents,
raloxifene and tamoxifen, for the prevention of disease
in women at increased breast cancer risk [10]. These
agents are especially effective in the prevention of breast
cancer among women who have AH. The highest TF
and Tn values were observed in women with DCIS, in
whom cure rates approach 100% with proper treatment
[11].
Based on our prediction models, the OR that a high
TF concentration predicted disease was highest (> 13.0)
for detecting 1) cancer vs. benign disease, and 2) AH or
cancer vs. benign disease. The models performed less
well in contrasting cancer with noncancer, in which AH
was included in the no cancer category. TF concentra-
tions in ND from women with AH appear to be more
Table 2 Disease Prediction Based on Groups
Group OR
1
TF Tn Menopausal
Status
All Subjects
AbNL vs. Benign 3.29* (1.29, 8.36) .81 (.33, 2.0) 2.19 (.95, 5.04)
CA vs, Benign 3.25* (1.27, 8.3) .84 (.34, 2.07) 2.23 (.96, 5.2)
CA vs. No CA 2.57* (1.10, 5.98) .82 (.32, 1.76) 2.0 (.91, 4.39)
OR
1
TF Tn Age
Premenopausal
AbNL vs. Benign .96 (.27, 3.39) 1.70 (.37,
7.81)
1.13** (1.03, 1.24)
CA vs, Benign .86 (.23, 3.18) 1.72 (.36,
8.16)
1.17** (1.05, 1.30)
CA vs. No CA .83 (.24, 2.84) 1.71 (.39,
7.48)
1.15** (1.04, 1.26)
Postmenopausal
AbNL vs. Benign 15.56** (2.39,
101.2)
.35 (.09, 1.38) 1.09* (1.01, 1.18)
CA vs, Benign 13.27** (2.08,
84.63)
.35 (.09, 1.38) 1.09* (1.02, 1.18)
CA vs. No CA 8.53** (1.78,
40.74)
.32 (.09, 1.17) 1.10** (1.02, 1.18)
1OR (odds ratios) are based on logistic regression models with log10
transformations of TF and Tn values and including menopausal (pre- vs. post)
status in the overall model and age in the pre- and post-menopausal group
models. 95% confidence intervals are in parentheses.
*Significant at the p ≤ .05 level; **p ≤ .01.
Figure 2 ROC curves for the prediction of breast atypia and
cancer in postmenopausal women. TF, Tn and age information
were used to generate curves comparing atypia or cancer
(abnormal) vs. benign disease (AUC = 0.83) (A), cancer vs. benign
disease (AUC = 0.83) (B), cancer vs. no cancer (AUC = 0.81) (C).
Sensitivity and 1-specificity are listed on the Y and × axes,
respectively.
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women with benign pathology. Figure 1 also suggests
that a high Tn concentration is consistent with AH or
more advanced disease.
The study had limitations. First, the ability of TF or
Tn to determine if a woman had AH was limited by the
small number of women in the study with AH. Second,
since only one ND sample collection was feasible in the
women who soon after sample collection had surgery on
the breast, we do not know the variability in TF or Tn
expression independent of disease. A study which col-
lects sequential ND samples from women at increased
breast cancer risk, including women with a biopsy
demonstrating AH, may help to address these
limitations.
Conclusions
TF and Tn are unique as biomarkers in that they are
carbohydrates, whereas most disease markers both in
use and undergoing evaluation are proteins. The expres-
sion of TF correlated with the presence of breast atypia
and cancer. A multicenter study should be conducted to
confirm our findings, and to determine the usefulness of
these markers in disease detection.
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